TY  - JOUR

T1  - P4-16-04: An Open-Label, Phase IIa, Non-Randomized Study of Radium-223 in Breast Cancer Patients with Bone Dominant Disease No Longer Considered Suitable for Endocrine Therapy.

JO  - Poster Session Abstracts

PY  - 2011/12/15

AU  - Coleman R

AU  - Flamen P

AU  - Naume B

AU  - Jerusalem G

AU  - Garcia C

AU  - Piccart M

AU  - OBryan-Tear CG

AU  - Aksnes A-K

ED  - 

DO  - DOI: 10.1158/0008-5472.sabcs11-p4-16-04

PB  - American Association for Cancer Research

Y2  - 2025/10/10

ER  -